ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation
Maintenance therapy with olaparib extended overall survival by nearly 13 months (12.9) compared with placebo…
